Delivering a biological payload, such as a vaccine, to the mucosa is a challenge: it is cleared quickly, before it can act.
LVT-NEXUS, our mucosal delivery platform, is built to meet that challenge. Designed to adapt to different payloads, it built on three components:
- The biological payload: for LVT-001, a protein based vaccine.
- LVT-ME, our proprietary muco-excipient. Biocompatible and biodegradable, it is designed to protect and deliver the payload within the mucosa to induce robust immune response.
- A dedicated nasal device, developed with Aptar Pharma, for simple, non-invasive, needle-free administration.